File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong

TitleResponse to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong
Authors
Issue Date2006
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/INT
Citation
Intervirology, 2006, v. 49 n. 1-2, p. 96-98 How to Cite?
AbstractData on the treatment efficacy of interferon (IFN)-α and ribavirin in patients with chronic hepatitis infected with hepatitis C virus (HCV) of genotype 6 are lacking. A study has been reported from Hong Kong which compared the treatment efficacy of IFN-α and ribavirin in the treatment of chronic HCV infection with genotypes 1 and 6. Twenty-four patients with HCV genotype 1 and 16 patients with HCV genotype 6 were studied. The baseline demographic data including median age, gender ratio, alanine aminotransferase levels, bilirubin levels, HCV RNA levels and histological scores were comparable between the two groups of patients. All patients received IFN-α 5 million units three times per week and ribavirin (1,000 mg for those weighing ≤75 kg and 1,200 mg for those weighing >75 kg) for 1 year. Patients infected with HCV genotype 6 achieved virological response significantly higher than those with HCV genotype 1 (67 vs. 33% at week 24, p = 0.02; 75 vs. 42% at the end of treatment, p = 0.05; 63 vs. 29% at 6 months after completion of treatment, p = 0.04). Histological improvement in inflammatory activity and fibrosis in the liver were observed in 25% and 25% of patients infected with HCV genotype 6 in contrast to only 13 and 8% in patients infected with HCV genotype 1; however, the differences were not statistically significant. In conclusion, patients with HCV genotype 6 gain a better response to combined treatment with IFN-α and ribavirin than those with HCV genotype 1 and achieve a significantly higher rate of sustained virological response. Copyright © 2006 S. Karger AG.
Persistent Identifierhttp://hdl.handle.net/10722/77741
ISSN
2015 Impact Factor: 1.822
2015 SCImago Journal Rankings: 0.781
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:35:13Z-
dc.date.available2010-09-06T07:35:13Z-
dc.date.issued2006en_HK
dc.identifier.citationIntervirology, 2006, v. 49 n. 1-2, p. 96-98en_HK
dc.identifier.issn0300-5526en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77741-
dc.description.abstractData on the treatment efficacy of interferon (IFN)-α and ribavirin in patients with chronic hepatitis infected with hepatitis C virus (HCV) of genotype 6 are lacking. A study has been reported from Hong Kong which compared the treatment efficacy of IFN-α and ribavirin in the treatment of chronic HCV infection with genotypes 1 and 6. Twenty-four patients with HCV genotype 1 and 16 patients with HCV genotype 6 were studied. The baseline demographic data including median age, gender ratio, alanine aminotransferase levels, bilirubin levels, HCV RNA levels and histological scores were comparable between the two groups of patients. All patients received IFN-α 5 million units three times per week and ribavirin (1,000 mg for those weighing ≤75 kg and 1,200 mg for those weighing >75 kg) for 1 year. Patients infected with HCV genotype 6 achieved virological response significantly higher than those with HCV genotype 1 (67 vs. 33% at week 24, p = 0.02; 75 vs. 42% at the end of treatment, p = 0.05; 63 vs. 29% at 6 months after completion of treatment, p = 0.04). Histological improvement in inflammatory activity and fibrosis in the liver were observed in 25% and 25% of patients infected with HCV genotype 6 in contrast to only 13 and 8% in patients infected with HCV genotype 1; however, the differences were not statistically significant. In conclusion, patients with HCV genotype 6 gain a better response to combined treatment with IFN-α and ribavirin than those with HCV genotype 1 and achieve a significantly higher rate of sustained virological response. Copyright © 2006 S. Karger AG.en_HK
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/INTen_HK
dc.relation.ispartofIntervirologyen_HK
dc.rightsIntervirology. Copyright © S Karger AG.en_HK
dc.subject.meshAntiviral Agents - administration & dosage - therapeutic useen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshFibrosis - pathologyen_HK
dc.subject.meshHepacivirus - genetics - isolation & purificationen_HK
dc.subject.meshHepatitis C - drug therapy - pathology - virologyen_HK
dc.subject.meshHong Kongen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInterferon-alpha - administration & dosage - therapeutic useen_HK
dc.subject.meshRNA, Viral - geneticsen_HK
dc.subject.meshRibavirin - administration & dosage - therapeutic useen_HK
dc.subject.meshSpecies Specificityen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshViremiaen_HK
dc.titleResponse to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kongen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0300-5526&volume=49&issue=1-2&spage=96&epage=8&date=2006&atitle=Response+to+combined+interferon+and+ribavirin+is+better+in+patients+infected+with+hepatitis+C+virus+genotype+6+than+genotype+1+in+Hong+Kong.en_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000087270en_HK
dc.identifier.pmid16166796-
dc.identifier.scopuseid_2-s2.0-24944488875en_HK
dc.identifier.hkuros122234en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-24944488875&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume49en_HK
dc.identifier.issue1-2en_HK
dc.identifier.spage96en_HK
dc.identifier.epage98en_HK
dc.identifier.isiWOS:000231911600015-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats